I often like your posts but this one is uneducated dribble apart from the line about your winnings.
Printable View
Perhaps this excellent summary of MAC's could be made a sticky at the start of the thread to serve as a guideline for any future input. It could be added to as things develop. Any posts not containing some reference to the above subjects, be it for or against, could be removed.
One that could be added is the reannouncement of the retracted cxbladder patent for Europe, should be due very soon. It was stated it would be awarded in February, I think.
I'm heartily sick of all the personal crap that's been going down (and I'm sure others are too) so can I suggest the "terms of trade" be published somewhere on the website and be made quite explicit e.g.
1st offence: A Warning
2nd offence: Banned for a week
Next offence after 1st ban: Siberia forever
Maybe that might ensure the content remains a little more sanitary - though I hope it wont disallow some of the humour that we all need to keep us sane.
Anyway back to Pacific Edge,
Thanks Hancock’s for posting the regional sales coverage, the comparison with this time last year shows good traction leading up to the end of the 31 March reporting season.
Six times as many sales staff may not translate to six times sales but there seems every reason to anticipate the start of the sales ramp up is well underway now.
Onward, forward and upward.
Attachment 7113
Actually with six times more staff I would hope that this would translate into a lot more than a 6x growth factor in sales, as product awareness would spread significantly quicker.
Looking at comparable company's the sales uptake is exponential in the first few years. Here's an example from a similar company in their space, i.e. cancer diagnostics (non-competing product):
Year 1 - 440 tests - Revenue $327k
Year 2 - 7000 tests - Revenue $4.823m
Year 3 - 14,500 tests - Revenue $27.006m
Year 4 - 24,450 tests - Revenue $62.745m
Year 5 - 39,640 tests - Revenue $108.658m
Year 6 - 49,030 tests - Revenue $146.581m
--- ---- --- --- --- --- --- ---
Year 10 - 85,510 tests - Revenue: $259.192m - Market Cap $825m USD.
Would be a pleasant thing Whipmoney for the company and patient shareholders after a few years of following all the good R&D to be rewarded like that.
Pacific Edge explained that it was a seven month process for the NPN’s to start reimbursement, which probably in all practicality marked the kick off whistle blow within FY15 year. Probably makes FY15 more like year one in that comparison.
Still though, analyst consensus for all that is for FY15 revenues of $3.2M, roughly equivalent to about 5,800 sales, have to sit tight and wait for the results now I guess.
Well folks--If there is anyone who feel they missed out on going back 14months and reading what has actually happened and what was predicted and by whom--now is your chance---i can assure you --it is an eye opener--This is reality==what has actually happened (and said) in what has led us up to where we are now.(Its very easy to skim over the bits that have gotten sidetracked)